BNP Paribas Bonus Zert AMD 27.06..../ DE000PE5PRD1 /
| 17/05/2024 21:40:11 | Chg.-0.030 | Bid21:58:12 | Ask21:58:12 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 73.220EUR | -0.04% | 73.240 Bid Size: 3,000 |
73.290 Ask Size: 3,000 |
ADVANCED MIC.DEV. D... | - - | 27/06/2024 | Call |
Newsfile Corp
16/05
FDA Grants AI-Powered Notal Vision Home OCT "SCANLY" De Novo Marketing Authorization
GlobeNewswire
15/05
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire
14/05
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire
14/05
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
13/05
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
13/05
AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire
09/05
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire
08/05
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire
08/05
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
08/05
AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire
08/05
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire
08/05
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire
07/05
Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire
07/05
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
06/05
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire
06/05
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire
06/05
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
